LAVA Therapeutics NV
Related Filers (5)
- Novo Holdings A/S (7)
- Redmile Group, LLC (3)
- Sanofi (1)
- Cooperatieve Gilde Healthcare IV U.A. (1)
- Versant Venture Capital VI, L.P. (1)
- Show More ...
Other (46)
6-K
Thursday, 11/16/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 8/22/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 8/15/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 6/15/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 6/8/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
144
Monday, 6/5/2023
Filing for proposed sale of securities under Rule 144
6-K
Monday, 4/24/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 4/12/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
20-F
Tuesday, 4/11/2023
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Monday, 3/13/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 2/16/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 2/6/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 1/9/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 1/6/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
20-F/A
Friday, 12/23/2022
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
CORRESP
Monday, 12/12/2022
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
6-K
Wednesday, 11/16/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 9/30/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 9/13/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 6/15/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 6/2/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 5/17/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
EFFECT
Thursday, 4/21/2022
Notice of Effectiveness
CORRESP
Wednesday, 4/20/2022
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
F-3
Tuesday, 4/12/2022
Registration statement for specified transactions by certain foreign private issuers
6-K
Monday, 3/28/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
20-F
Thursday, 3/24/2022
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Friday, 1/7/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 11/15/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/13/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 8/16/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 5/20/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
F-1/A
Wednesday, 3/24/2021
Registration statement for securities of certain foreign private issuers
CERT
Wednesday, 3/24/2021
Certification by an exchange approving securities for listing
EFFECT
Wednesday, 3/24/2021
Notice of Effectiveness
SEC STAFF LETTER
Wednesday, 3/24/2021
None
CORRESP
Tuesday, 3/23/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
CORRESP
Monday, 3/22/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
CORRESP
Monday, 3/22/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
CORRESP
Thursday, 3/18/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
F-1/A
Thursday, 3/18/2021
Registration statement for securities of certain foreign private issuers
8-A12B
Thursday, 3/18/2021
Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
CORRESP
Wednesday, 3/10/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
SEC STAFF LETTER
Wednesday, 3/3/2021
None
CORRESP
Tuesday, 3/2/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
F-1
Tuesday, 3/2/2021
Registration statement for securities of certain foreign private issuers
Ownership (12)
SC 13G/A
Wednesday, 2/14/2024
Redmile Group, LLC: Major Shareholders
SC 13D/A
Thursday, 11/9/2023
Novo Holdings A/S: Major Shareholders
SC 13D/A
Tuesday, 6/6/2023
Novo Holdings A/S: Major Shareholders
SC 13D/A
Friday, 2/24/2023
Novo Holdings A/S: Major Shareholders
SC 13D/A
Monday, 10/3/2022
Novo Holdings A/S: Major Shareholders
SC 13D/A
Friday, 9/30/2022
Novo Holdings A/S: Major Shareholders
SC 13G/A
Monday, 2/14/2022
Redmile Group, LLC: Major Shareholders
SC 13G
Thursday, 4/8/2021
Redmile Group, LLC: Major Shareholders
SC 13D
Thursday, 4/8/2021
Versant Venture Capital VI, L.P.: Major Shareholders
SC 13D
Wednesday, 3/31/2021
Cooperatieve Gilde Healthcare IV U.A.: Major Shareholders
SC 13G
Wednesday, 3/31/2021
Sanofi: Major Shareholders
SC 13D
Wednesday, 3/31/2021
Novo Holdings A/S: Major Shareholders
Prospectus (3)
S-8
Friday, 5/28/2021
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B4
Friday, 3/26/2021
Prospectus filed pursuant to Rule 424(b)(4)
DRS
Monday, 1/25/2021
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy